Latest Breaking News On - Cedric francois - Page 4 : comparemela.com

Apellis working through continued challenges with Syfovre launch

Apellis working through continued challenges with Syfovre launch
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United statesCedric francoisTim sullivanMadam townsendAstella izervayChief financial officer tim sullivanChief operating officer adamMedical productsHuman use

Apellis Pharmaceuticals Inc (APLS) Reports Robust Revenue Growth in 2023

Financial Position: The company ended the year with $351 million in cash and cash equivalents. On February 27, 2024, Apellis Pharmaceuticals Inc (NASDAQ:APLS) released its 8-K filing, detailing the financial results for the fourth quarter and full year of 2023. The clinical-stage biopharmaceutical company, known for its novel therapeutic compounds targeting the complement system, reported a substantial increase in revenues, primarily attributed to the launch of SYFOVRE (pegcetacoplan injection) and sales of EMPAVELI (pegcetacoplan).

Cedric francoisApellis pharmaceuticals incFinancial highlightsApellis pharmaceuticals incAsh and cash equivalentsFinancial resultsCedric francois

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® and $91 million for EMPAVELI® Strong SYFOVRE launch, with more than 160,000 total doses distributed in 2023.

United statesLissa pavlukCedric francoisMeredith kayaAmerican academy of ophthalmologyExchange commissionApellis pharmaceuticals incAmerican society of nephrologyEuropean unionExchange commission onCommittee for medicinal products human useEuropean medicines agencyAdvisory committee on immunization practicesAmerican society of hematologyRecent business highlightsAmerican academy

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Sees Large Drop in Short Interest

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 10,670,000 shares, a decline of 11.3% from the January 15th total of 12,030,000 shares. Based on an average daily trading volume, of 2,100,000 shares, the days-to-cover […]

Robertw bairdJames george chopasCedric francoisAltitude crest partners incWells fargo companyNews ratings for apellis pharmaceuticals dailyInstitutional trading of apellis pharmaceuticalsApellis pharmaceuticals company profileWoodward diversified capitalApellis pharmaceuticals incBellevue groupInsider transactions at apellis pharmaceuticalsApellis pharmaceuticalsApellis pharmaceuticals stockPathstone holdingsSecurities exchange commission

Apellis Pharmaceuticals (NASDAQ:APLS) Raised to Buy at Jefferies Financial Group

Apellis Pharmaceuticals (NASDAQ:APLS) Raised to Buy at Jefferies Financial Group
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesAlec machielsCedric francoisT rowe price investment management incInstitutional trading of apellis pharmaceuticalsNeedham companyWells fargo companyJefferies financial groupApellis pharmaceuticals incApellis pharmaceuticalsApellis pharmaceuticals stock downBlackrock incJennison associatesVanguard group incSecurities exchange commissionPricet rowe associates inc